Susquehanna International Group
CAMP icon

Susquehanna International Group’s CAMP4 Therapeutics CAMP Stock Holding History

Susquehanna International Group’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-336,047
Closed -$1.48M – 13447
2026
Q1 		$1.48M Buy
+336,047
New +$1.6M ﹤0.01% 6914

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna International Group's CAMP Position: Q2 2026 in Review

Susquehanna International Group sold out of CAMP4 Therapeutics (CAMP) in Q2 2026, closing a stake of 336,047 shares — an estimated $1.48M sold.

Susquehanna International Group first reported a position in CAMP in Q1 2026 and held it in 1 quarter. The position peaked at $1.48M in Q1 2026. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Susquehanna International Group reported no remaining CAMP4 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Susquehanna International Group sold 336,047 CAMP4 Therapeutics shares in Q2 2026, an estimated $1.48M.
  • Susquehanna International Group first reported a position in CAMP4 Therapeutics in Q1 2026 and held it in 1 quarter.
  • Susquehanna International Group's CAMP4 Therapeutics position peaked at $1.48M in Q1 2026.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.